Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease

This publication has 78 references indexed in Scilit:

• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
  Biochemical and Biophysical Research Communications, 1998
• Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell Cultures
  Biochemical and Biophysical Research Communications, 1998
• American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
  Arthritis & Rheumatism, 1995
• Molecular Cloning of Human cDNA for Cathepsin K: Novel Cysteine Proteinase Predominantly Expressed in Bone
  Biochemical and Biophysical Research Communications, 1995
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
  Arthritis & Rheumatism, 1993
• In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin‐1β
  Arthritis & Rheumatism, 1992
• Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface.
  The Journal of cell biology, 1991
• Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.
  The Journal of Experimental Medicine, 1985